[2]He X, Hou L, Bai J, et al. Trastuzumab deruxtecan (DS8201) for advanced non-small cell lung cancer with HER2 exon 20 insertion mutation: a case report[J]. Anticancer Drugs. 2024 Jan 1;35(1):101-108. doi: 10.1097/CAD.0000000000...
他们开发了既能有效抑制HER2第20号外显子突变体,又对野生型EGFR具有高度选择性的新型共价TKIs。在体外研究中,这些TKIs能减少肿瘤细胞的存活和增殖,抑制HER2第20号外显子突变的NSCLC异种移植肿瘤模型的生长,同时抑制HER2下游信号传导。 这...
1. Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study. J Clin Oncol. 2020;38(24):2753-2761.2. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded a...
例如,HER2外显子20插入突变(HER2 exon 20 insertion mutation)是一种罕见的肺癌驱动基因突变,约占非小细胞肺癌(NSCLC)的2%~4%,这类患者对现有的HER2靶向药物和化疗药物都不敏感,预后非常差。 幸运的是,最近有一款新的靶向药物波奇替尼(Poziotinib)在临床试验中显示出了令人振奋的效果。波奇替尼是一种口服的酪...
He X, Hou L, Bai J, Sun C, Wang D, An G. Trastuzumab deruxtecan (DS8201) for advanced non-small cell lung cancer with HER2 exon 20 insertion mutation: a case report. Anticancer Drugs. 2024 Jan 1;35(1):101-108. doi: 10.1097/CAD.0000000000001535. Epub 2023 Aug 25. PMID: 37615532...
3.Trastuzumab deruxtecan (DS8201) for advanced non-small cell lung cancer with HER2 exon 20 insertion mutation: a case report - PMC (nih.gov)4.Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer | New England Journal of Medicine (nejm.org)免责声明:康和源免疫之家为免疫科普...
[24].Tan AC, Saw SPL, Chen J, et al. Clinical and Genomic Features of HER2 Exon 20 Insertion Mutations and Characterization of HER2 Expression by Immunohistochemistry in East Asian Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2022;6:e2200278. doi:10.1200/PO.22.00278 ...
1. Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives 2. Pulse Afatinib for ERBB2 Exon 20 Insertion–Mutated Lung Adenocarcinomas 3. .Li B, Shen R, Buonocore Z, et al. Phase 2 basket trial of ado-trastuzumab emtansine in patients with HER2 muta...
The FDA has accepted for review a new drug application for poziotinib in patients with previously treated locally advanced or metastatic non–small cell lung cancer with HER2 exon 20 insertion mutations. The FDA has accepted for review a new drug application (NDA) for poziotinib in patients ...
[2]T.M. Kim, N. Girard, G.K.M. Low, et al. Amivantamab vs real-world(RW) therapy in Japanese patients with advanced non-small cell lung cancer (aNSCLC) epidermal growth factor receptor (EGFR) exon-20 insertion mutation (E20i). ESMO2022, 1109P. ...